PET scan with a tracer for liver, bile duct, or neuroendocrine tumors
Part of Cancer, Digestive system clinical trials.
This trial uses a special PET scan tracer (zirconium-labelled girentuximab) to see if it can find and track certain liver, bile duct, and pancreatic/intestinal neuroendocrine tumors. It may help doctors better understand your cancer and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer, bile duct cancer, or a specific type of neuroendocrine tumor that has gotten worse or has certain genetic features.
- You are 18 years or older.
- You have at least one tumor that can be seen on a CT or MRI scan.
- You are well enough to be up and about at least half the day (ECOG score 0, 1, or 2).
- You have not had certain cancer treatments (chemotherapy, radiation, immunotherapy) in the last 2 weeks.
- You do not have serious heart disease, uncontrolled infections, or other major health problems that would make the scan unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET imaging method that uses two different tracers to find and stage liver cancer (HCC) or neuroendocrine tumors (GEP-NET) more accurately. It may help doctors decide on the best treatment for you.
This trial tests a new imaging technique that may help doctors see liver cancer more clearly. It uses a special tracer that targets a protein found on many liver cancer cells. This could help with diagnosis and monitoring.
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.